MedTrace Logo

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

NCT04810182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2024-02-08

No results posted yet for this study

Summary

This study aims to analyze the role the of Regorafenib in prolonging the Overall Survival of glioblastoma multiforme patients who progressed after surgery and a first-line chemo-radiotherapy treatment in the setting of "real world life".

Conditions

Interventions

DRUG

Regorafenib 40 MG Oral Tablet [STIVARGA]

As per the treating physicians discretion

Sponsors & Collaborators

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810182 on ClinicalTrials.gov